1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
Daiichi Sankyo and partner AstraZeneca said on October 17 that the US FDA has granted a priority review status for their hoped-to-be-blockbuster breast cancer drug trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate (ADC), with the agency’s decision expected by mid-next…
To read the full story
Related Article
- Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
December 24, 2019
- Daiichi Sankyo’s Big-Seller Hopeful DS-8201 Filed in Japan
September 10, 2019
BUSINESS
- CureApp’s Alcoholism Therapy App Approved in Japan
February 19, 2025
- Japan Approves Shionogi’s Therapy App for Pediatric ADHD
February 19, 2025
- Kyorin Nabs Japan Option for Cyrano’s Post-Viral Smell Loss Drug
February 19, 2025
- COVID Shot Kostaive Lands EU Approval, 1st Nod Outside Japan
February 19, 2025
- Boehringer Files Zongertinib in Japan for HER2 Lung Cancer
February 19, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…